DUBLIN--(BUSINESS WIRE)--The "China CDMO (Contract Development & Manufacturing Organization) Industry Research Report, 2018-2021" report has been added to ResearchAndMarkets.com's offering.
China's pharmaceutical R&D industry started late, with insufficient technical capacity and fewer investment at the initial stage of development. However, it has achieved rapid development in recent years and has great room for improvement. In 2017, China invested approximately US $13.2 billion in medical R&D, accounting for 8.9 percent of the total global medical R&D investment in the same period. With the improvement of Chinese drug firms' R&D strength and the strengthening of government control of generic drugs, such as development of the generic consistency evaluation, the clinical trial data of audits and inspections, etc., the Chinese pharmaceutical R&D spending will continue to increase. China's pharmaceutical R&D spending is expected to reach US $29.2 billion in 2021, accounting for the total amount of the global pharmaceutical R&D spending will rise to 18.3%.
The global market for drug development services reached about US $71.7 billion in 2017.At a time when the cost of developing new drugs is high and generic competition is fierce around the world, pharmaceutical companies are increasingly inclined to outsource drug development to speed up the development of new drugs. The global market for drug development services is expected to grow to US $102.8 billion by 2021.
Compared with the global pharmaceutical development service market, the volume of China's pharmaceutical development service market is small, but the growth is fast. In 2017, China's drug development services market size reached approximately US $79.2 billion, and is expected to increase by 2021 to $27.8 billion.
- STA Pharmaceutical
- WuXi Biologics
- Porton Fine Chemicals
Key Topics Covered:
1. Overview of Contract Development & Manufacturing Organization
3. Background of CDMO Industry
4 CDMO Market
5 CDMO Players in China
6 Industry Development Trends
For more information about this report visit https://www.researchandmarkets.com/research/pzgbgz/chinas_contract?w=4